CN1298383C - Medicine for treating neurasthenia and its preparation method - Google Patents
Medicine for treating neurasthenia and its preparation method Download PDFInfo
- Publication number
- CN1298383C CN1298383C CNB2005100098886A CN200510009888A CN1298383C CN 1298383 C CN1298383 C CN 1298383C CN B2005100098886 A CNB2005100098886 A CN B2005100098886A CN 200510009888 A CN200510009888 A CN 200510009888A CN 1298383 C CN1298383 C CN 1298383C
- Authority
- CN
- China
- Prior art keywords
- radix
- rhizoma
- group
- fructus
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a medicine for treating neurasthenia and a preparation method thereof, which relates to medicine composition for treating neurasthenia and a preparation method. The medicine of the present invention comprises the following raw material according to weight number, wherein an A group comprises 4 to 10 of american ginseng, 2 to 9 of polygala, 2 to 9 of aucklandia roots, 2 to 9 of antler, and 4 to 10 of nacre; a B group comprises 3 to 10 of bupleurum roots, 3 to 10 of radix paeoniae alba, 3 to 10 of prepared tuber of pinellia, 3 to 10 of Job's tears seeds, 3 to 10 of shizandra, 3 to 10 of caulis polygoni multiflori, 3 to 10 of lilies, 3 to 10 of rehmannia roots, 3 to 10 of gastrodia tubers, 3 to 10 of rhynohophylla, 2 to 9 of rush pith, 2 to 9 of bamboo shavings, 2 to 9 of prunella spike, 2 to 9 of feverfew, 3 to 10 of blighted wheat, 2 to 9 of Chinese dates, and 2 to 9 of liquorice. The present invention has the method that the raw material powder of the A group is uniformly mixed and stirred with the raw material clear plaster of the B group, and water-paste pills can be manufactured. The medicine of the present invention has the advantages of exact neurasthenia treatment action, high cure rate, no dependence and no toxicity and side effect. The method of the present invention has the advantage of high extraction rate of effective components of medicine.
Description
Technical field:
The present invention relates to a kind of compositions of the neurasthenia's of treatment medicine and manufacture method is provided.
Background technology:
The neurasthenia is clinical common and disease that heal than refractory, and sickness rate is the trend that rises year by year, does not more form obstinate asomnia for a long time.This disease of neurasthenia in motherland's medical science, belong to be insomnia, strongly fragrant disease, Bulbus Lilii syndrome, climacteric syndrome category.The cause of disease is owing to happiness, anger, melancholy, think of, compassion, fears, shies damaged by excess of seven emotions, is the neurasthenia and cause function of five internal organs imbalance initiation, and the neurasthenia deficient syndrome is more than the case of a physically strong patient running a high fever.The existing following problem of medicine (comprising Chinese medicine, Western medicine) ubiquity that is used for the treatment of neurasthenia: one, the therapeutical effect of some medicine is imprecise, and patient takes medicine by package insert or doctor's advice and often can not take effect.Though two, some medicine instant effect, it is not lasting to act on, and must adhere to for a long time taking medicine, and patient is felt exhausted curative effect is descended.Though three, some medicine is effective in cure, can not cure, in case drug withdrawal is promptly fallen ill, make patient produce dependency easily.Four, some poison of drug side effect is bigger, takes for a long time the healthy of patient done harm rather than good.
Summary of the invention:
The objective of the invention is that the therapeutical effect that exists for the medicine that solves existing treatment neurasthenia is imprecise, effect is lasting, toxic and side effects is big, be easy to generate dependent problem, a kind of medicine for the treatment of neurasthenia and preparation method thereof is provided, and medicine of the present invention has that therapeutical effect is definite, cure rate is high, no dependence, the characteristics that have no side effect.Method of the present invention has the high characteristics of effective ingredient extraction ratio.Medicine of the present invention is made by following raw materials by weight portion, and wherein the A group is: Radix Panacis Quinquefolii: 4～10, Radix Polygalae: 2～9, the Radix Aucklandiae: 2～9, Cornu Cervi Pantotrichum: 2～9, Concha Margaritifera: 4～10, Dens Draconis: 4～10, Concha Ostreae: 3～10, Semen Ziziphi Spinosae (parched): 4～10, succinum: 3～9, Magnetitum: 3～9, Massa Medicata Fermentata: 2～8, Fructus Citri Sarcodactylis: 2～8, Poria cum Radix Pini: 3～10, Ganoderma: 4～10, Radix Curcumae: 3～10, Moschus: 1～8; The B group is: Radix Bupleuri: 3～10, the Radix Paeoniae Alba: 3～10, Rhizoma Pinelliae Preparatum: 3～10, Semen Coicis: 3～10, Fructus Schisandrae Chinensis: 3～10, Caulis Polygoni Multiflori: 3～10, Bulbus Lilii: 3～10, the Radix Rehmanniae: 3～10, Rhizoma Gastrodiae: 3～10, Ramulus Uncariae Cum Uncis: 3～10, Medulla Junci: 2～9, Caulis Bambusae In Taenia: 2～9, Spica Prunellae: 2～9, Flos Chrysanthemi: 2～9, Fructus Tritici Levis: 3～10, Fructus Jujubae: 2～9, Radix Glycyrrhizae: 2～9, Folium Pini: 2～9, Rhizoma Acori Graminei: 3～10, Folium Kaki: 2～9, Rhizoma et radix valerianae: 3～10, Flos Albiziae: 2～9, Fructus Gardeniae: 2～9, Radix Angelicae Sinensis: 2～9, the Radix Astragali: 3～10, Carapax et Plastrum Testudinis (Carapax et Plastrum Testudinis): 2～9, Rhizoma Dioscoreae: 2～9, Radix Ophiopogonis: 3～10.Manufacture method of the present invention is: it is standby that the raw material powder of A group is broken into 100～150 purpose fine powders, the raw material water of B group is decocted twice, merge decoction liquor twice, being concentrated into relative density is the clear paste of 1.2～1.3 (60～65 ℃), the clear paste mixing and stirring of material powder that A is organized and B group raw material is made the watered pill and is got final product then.The present invention is divided into A group and B group with the raw material of medicine, according to the processing technology difference it is separated.Clinical practice proves that the medicine material of B group must can propose its effective ingredient through water extraction, reaches good curative effect.
For showing the curative effect of medicine of the present invention, see also following clinical data to the treatment neurasthenia:
One, physical data: select 87 routine neurasthenia patients at random, male patient 42 people wherein, minimum 17 years old of age, maximum 70 years old, average 37.3 years old; Female patient 45 people, minimum 18 years old, maximum 68 years old, average 34.1 years old.The course of disease is the shortest 6 months, and is the longest 2.5 years.
Two, diagnostic criteria: 1, patient's brain is easily tired, poor memory.2, easily worried, be nervous and can not relax, LA or depression are arranged.3, spirit is easily excited, shows as to recall and association increases and loses control of, and excitement can have unplessantness displeasure.4, with tension headache.5, sleep disorder, as difficulty falling asleep, by dream hardship, the easy early awakening that is difficult to sleep soundly still feels tired after waking up.6,, not normal as the rhythm of the heart, blood pressure is higher or on the low side, hyperhidrosis, acra are felt cold, anorexia, constipation or diarrhoea, menoxenia, seminal emission, premature ejaculation or sexual impotence with autonomic nervous dysfunction.
Three, administrated method: take medicine for early, middle and late three times, take medicine of the present invention (watered pill) 10g morning, respectively obey 20g before noon, the supper, after sb.'s illness took a favorable turn, early, middle and lately respectively obey 10g, note having a rest on time, avoid feelings will to stimulate, 30 days is a course of treatment.
Four, criterion of therapeutical effect: 1, the one night sleep was recovery from illness in 7～8 hours.Slept 6 hours, but few dream in the sleep, can reach the deep sleep, the back of waking up is energetic also to be recovery from illness; 2, sleep 5 hours and few dream are produce effects; 3, sleep was effective in 4 hours; 4, sleep be invalid in 2～3 hours, but was effective for the person of lying awake all night before treating.
Five, efficacy analysis: 87 routine patients person 55 people that wherein do not lie awake all night through a course of therapy 21 people that fully recover, account for 38.18%; Produce effects 12 people account for 21.82%; Effective 22 people account for 40%; Through two course of therapy, 27 people that fully recover, account for 49.09%; Produce effects 5 people account for 9.09%; Effective 2 people account for 3.64%.Surplus 32 people all for sleeping at 2～4 hours, and through a course of therapy, 23 people that fully recover account for 71.88%; Produce effects 4 people account for 12.5%; Effective 5 people account for 15.62%.Through two course of therapy, 7 people that fully recover account for 21.88%; Produce effects 2 people account for 6.25%.Recovery from illness 78 people in 87 routine patients, cure rate is 89.66%; Produce effects 7 people account for 8.05%; Effective 2 people account for 2.03%, and total effective rate is 100%.All cases all promptly began to take effect after medication in 3～5 days.
Medicine of the present invention has regulating the flow of QI to alleviate depression, brain-care, tranquilizing by nourishing the heart, nourishing and fit keeping function, enhancing immunity, defying age, and the effect of YANG hyperactivity suppressing blood pressure lowering is arranged.But it is useful and do not have overslaugh to hypotension and normal arterial pressure.The present invention has that the effect of treatment neurasthenia is definite, cure rate is high, no dependence, the advantage that has no side effect.
The specific embodiment:
The specific embodiment one: present embodiment is made by following raw materials by weight portion, and wherein the A group is: Radix Panacis Quinquefolii: 4～10, Radix Polygalae: 2～9, the Radix Aucklandiae: 2～9, Cornu Cervi Pantotrichum: 2～9, Concha Margaritifera: 4～10, Dens Draconis: 4～10, Concha Ostreae: 3～10, Semen Ziziphi Spinosae (parched): 4～10, succinum: 3～9, Magnetitum: 3～9, Massa Medicata Fermentata: 2～8, Fructus Citri Sarcodactylis: 2～8, Poria cum Radix Pini: 3～10, Ganoderma: 4～10, Radix Curcumae: 3～10, Moschus: 1～8; The B group is: Radix Bupleuri: 3～10, the Radix Paeoniae Alba: 3～10, Rhizoma Pinelliae Preparatum: 3～10, Semen Coicis: 3～10, Fructus Schisandrae Chinensis: 3～10, Caulis Polygoni Multiflori: 3～10, Bulbus Lilii: 3～10, the Radix Rehmanniae: 3～10, Rhizoma Gastrodiae: 3～10, Ramulus Uncariae Cum Uncis: 3～10, Medulla Junci: 2～9, Caulis Bambusae In Taenia: 2～9, Spica Prunellae: 2～9, Flos Chrysanthemi: 2～9, Fructus Tritici Levis: 3～10, Fructus Jujubae: 2～9, Radix Glycyrrhizae: 2～9, Folium Pini: 2～9, Rhizoma Acori Graminei: 3～10, Folium Kaki: 2～9, Rhizoma et radix valerianae: 3～10, Flos Albiziae: 2～9, Fructus Gardeniae: 2～9, Radix Angelicae Sinensis: 2～9, the Radix Astragali: 3～10, Carapax et Plastrum Testudinis (Carapax et Plastrum Testudinis): 2～9, Rhizoma Dioscoreae: 2～9, Radix Ophiopogonis: 3～10.The manufacture method of present embodiment is: it is standby that the raw material powder of A group is broken into 100～150 purpose fine powders, the raw material water of B group is decocted twice, merge decoction liquor twice, being concentrated into relative density is the clear paste of 1.2～1.3 (60～65 ℃), the clear paste mixing and stirring of material powder that A is organized and B group raw material is made the watered pill and is got final product then.
The specific embodiment two: present embodiment is made by following raw materials by weight portion, and wherein the A group is: Radix Panacis Quinquefolii: 4.5～9.5, Radix Polygalae: 2.5～8.5, the Radix Aucklandiae: 2.5～8.5, Cornu Cervi Pantotrichum: 2.5～8.5, Concha Margaritifera: 4.5～9.5, Dens Draconis: 4.5～9.5, Concha Ostreae: 3.5～9.5, Semen Ziziphi Spinosae (parched): 4.5～9.5, succinum: 3.5～8.5, Magnetitum: 3.5～8.5, Massa Medicata Fermentata: 2.5～7.5, Fructus Citri Sarcodactylis: 2.5～7.5, Poria cum Radix Pini: 3.5～9.5, Ganoderma: 4.5～9.5, Radix Curcumae: 3.5～9.5, Moschus: 1.5～7.5; The B group is: Radix Bupleuri: 3.5～9.5, the Radix Paeoniae Alba: 3.5～9.5, Rhizoma Pinelliae Preparatum: 3.5～9.5, Semen Coicis: 3.5～9.5, Fructus Schisandrae Chinensis: 3.5～9.5, Caulis Polygoni Multiflori: 3.5～9.5, Bulbus Lilii: 3.5～9.5, the Radix Rehmanniae: 3.5～9.5, Rhizoma Gastrodiae: 3.5～9.5, Ramulus Uncariae Cum Uncis: 3.5～9.5, Medulla Junci: 2.5～8.5, Caulis Bambusae In Taenia: 2.5～8.5, Spica Prunellae: 2.5～8.5, Flos Chrysanthemi: 2.5～8.5, Fructus Tritici Levis: 3.5～9.5, Fructus Jujubae: 2.5～8.5, Radix Glycyrrhizae: 2.5～8.5, Folium Pini: 2.5～8.5, Rhizoma Acori Graminei: 3.5～9.5, Folium Kaki: 2.5～8.5, Rhizoma et radix valerianae: 3.5～9.5, Flos Albiziae: 2.5～8.5, Fructus Gardeniae: 2.5～8.5, Radix Angelicae Sinensis: 2.5～8.5, the Radix Astragali: 3.5～9.5, Carapax et Plastrum Testudinis (Carapax et Plastrum Testudinis): 2.5～8.5, Rhizoma Dioscoreae: 2.5～8.5, Radix Ophiopogonis: 3.5～9.5.Other method is identical with the specific embodiment one.
The specific embodiment three: present embodiment is made by following raw materials by weight portion, and wherein the A group is: Radix Panacis Quinquefolii: 4.9～9.1, Radix Polygalae: 2.9～8.1, the Radix Aucklandiae: 2.9～8.1, Cornu Cervi Pantotrichum: 2.9～8.1, Concha Margaritifera: 4.9～9.1, Dens Draconis: 4.9～9.1, Concha Ostreae: 3.9～9.1, Semen Ziziphi Spinosae (parched): 4.9～9.1, succinum: 3.9～8.1, Magnetitum: 3.9～8.1, Massa Medicata Fermentata: 2.9～7.1, Fructus Citri Sarcodactylis: 2.9～7.1, Poria cum Radix Pini: 3.9～9.1, Ganoderma: 4.9～9.1, Radix Curcumae: 3.9～9.1, Moschus: 1.9～7.1; The B group is: Radix Bupleuri: 3.9～9.1, the Radix Paeoniae Alba: 3.9～9.1, Rhizoma Pinelliae Preparatum: 3.9～9.1, Semen Coicis: 3.9～9.1, Fructus Schisandrae Chinensis: 3.9～9.1, Caulis Polygoni Multiflori: 3.9～9.1, Bulbus Lilii: 3.9～9.1, the Radix Rehmanniae: 3.9～9.1, Rhizoma Gastrodiae: 3.9～9.1, Ramulus Uncariae Cum Uncis: 3.9～9.1, Medulla Junci: 2.9～8.1, Caulis Bambusae In Taenia: 2.9～8.1, Spica Prunellae: 2.9～8.1, Flos Chrysanthemi: 2.9～8.1, Fructus Tritici Levis: 3.9～9.1, Fructus Jujubae: 2.9～8.1, Radix Glycyrrhizae: 2.9～8.1, Folium Pini: 2.9～8.1, Rhizoma Acori Graminei: 3.9～9.1, Folium Kaki: 2.9～8.1, Rhizoma et radix valerianae: 3.9～9.1, Flos Albiziae: 2.9～8.1, Fructus Gardeniae: 2.9～8.1, Radix Angelicae Sinensis: 2.9～8.1, the Radix Astragali: 3.9～9.1, Carapax et Plastrum Testudinis (Carapax et Plastrum Testudinis): 2.9～8.1, Rhizoma Dioscoreae: 2.9～8.1, Radix Ophiopogonis: 3.9～9.1.Other method is identical with the specific embodiment one.
The specific embodiment four: present embodiment is made by following raw materials by weight portion, and wherein the A group is: Radix Panacis Quinquefolii: 5, Radix Polygalae: 4, the Radix Aucklandiae: 4, Cornu Cervi Pantotrichum: 4, Concha Margaritifera: 5, Dens Draconis: 5, Concha Ostreae: 5, Semen Ziziphi Spinosae (parched): 5, succinum: 5, Magnetitum: 5, Massa Medicata Fermentata: 4, Fructus Citri Sarcodactylis: 4, Poria cum Radix Pini: 5, Ganoderma: 5, Radix Curcumae: 5, Moschus: 3; The B group is: Radix Bupleuri: 5, the Radix Paeoniae Alba: 5, Rhizoma Pinelliae Preparatum: 5, Semen Coicis: 5, Fructus Schisandrae Chinensis: 5, Caulis Polygoni Multiflori: 5, Bulbus Lilii: 5, the Radix Rehmanniae: 5, Rhizoma Gastrodiae: 5, Ramulus Uncariae Cum Uncis: 5, Medulla Junci: 4, Caulis Bambusae In Taenia: 4, Spica Prunellae: 4, Flos Chrysanthemi: 4, Fructus Tritici Levis: 5, Fructus Jujubae: 4, Radix Glycyrrhizae: 4, Folium Pini: 4, Rhizoma Acori Graminei: 5, Folium Kaki: 4, Rhizoma et radix valerianae: 5, Flos Albiziae: 4, Fructus Gardeniae: 4, Radix Angelicae Sinensis: 4, the Radix Astragali: 5, Carapax et Plastrum Testudinis (Carapax et Plastrum Testudinis): 4, Rhizoma Dioscoreae: 4, Radix Ophiopogonis: 5.Other method with
The specific embodiment one is identical.
Claims (5)
1, a kind of medicine for the treatment of neurasthenia, it is characterized in that making raw materials of effective components is A group and B group, count by weight, the A group is: Radix Panacis Quinquefolii: 4～10, Radix Polygalae: 2～9, the Radix Aucklandiae: 2～9, Cornu Cervi Pantotrichum: 2～9, Concha Margaritifera: 4～10, Dens Draconis: 4～10, Concha Ostreae: 3～10, Semen Ziziphi Spinosae (parched): 4～10, succinum: 3～9, Magnetitum: 3～9, Massa Medicata Fermentata: 2～8, Fructus Citri Sarcodactylis: 2～8, Poria cum Radix Pini: 3～10, Ganoderma: 4～10, Radix Curcumae: 3～10, Moschus: 1～8; The B group is: Radix Bupleuri: 3～10, the Radix Paeoniae Alba: 3～10, Rhizoma Pinelliae Preparatum: 3～10, Semen Coicis: 3～10, Fructus Schisandrae Chinensis: 3～10, Caulis Polygoni Multiflori: 3～10, Bulbus Lilii: 3～10, the Radix Rehmanniae: 3～10, Rhizoma Gastrodiae: 3～10, Ramulus Uncariae Cum Uncis: 3～10, Medulla Junci: 2～9, Caulis Bambusae In Taenia: 2～9, Spica Prunellae: 2～9, Flos Chrysanthemi: 2～9, Fructus Tritici Levis: 3～10, Fructus Jujubae: 2～9, Radix Glycyrrhizae: 2～9, Folium Pini: 2～9, Rhizoma Acori Graminei: 3～10, Folium Kaki: 2～9, Rhizoma et radix valerianae: 3～10, Flos Albiziae: 2～9, Fructus Gardeniae: 2～9, Radix Angelicae Sinensis: 2～9, the Radix Astragali: 3～10, Carapax et Plastrum Testudinis: 2～9, Rhizoma Dioscoreae: 2～9, Radix Ophiopogonis: 3～10.
2, a kind of medicine for the treatment of neurasthenia according to claim 1 is characterized in that the A group is: Radix Panacis Quinquefolii: 4.5～9.5, Radix Polygalae: 2.5～8.5, the Radix Aucklandiae: 2.5～8.5, Cornu Cervi Pantotrichum: 2.5～8.5, Concha Margaritifera: 4.5～9.5, Dens Draconis: 4.5～9.5, Concha Ostreae: 3.5～9.5, Semen Ziziphi Spinosae (parched): 4.5～9.5, succinum: 3.5～8.5, Magnetitum: 3.5～8.5, Massa Medicata Fermentata: 2.5～7.5, Fructus Citri Sarcodactylis: 2.5～7.5, Poria cum Radix Pini: 3.5～9.5, Ganoderma: 4.5～9.5, Radix Curcumae: 3.5～9.5, Moschus: 1.5～7.5; The B group is: Radix Bupleuri: 3.5～9.5, the Radix Paeoniae Alba: 3.5～9.5, Rhizoma Pinelliae Preparatum: 3.5～9.5, Semen Coicis: 3.5～9.5, Fructus Schisandrae Chinensis: 3.5～9.5, Caulis Polygoni Multiflori: 3.5～9.5, Bulbus Lilii: 3.5～9.5, the Radix Rehmanniae: 3.5～9.5, Rhizoma Gastrodiae: 3.5～9.5, Ramulus Uncariae Cum Uncis: 3.5～9.5, Medulla Junci: 2.5～8.5, Caulis Bambusae In Taenia: 2.5～8.5, Spica Prunellae: 2.5～8.5, Flos Chrysanthemi: 2.5～8.5, Fructus Tritici Levis: 3.5～9.5, Fructus Jujubae: 2.5～8.5, Radix Glycyrrhizae: 2.5～8.5, Folium Pini: 2.5～8.5, Rhizoma Acori Graminei: 3.5～9.5, Folium Kaki: 2.5～8.5, Rhizoma et radix valerianae: 3.5～9.5, Flos Albiziae: 2.5～8.5, Fructus Gardeniae: 2.5～8.5, Radix Angelicae Sinensis: 2.5～8.5, the Radix Astragali: 3.5～9.5, Carapax et Plastrum Testudinis: 2.5～8.5, Rhizoma Dioscoreae: 2.5～8.5, Radix Ophiopogonis: 3.5～9.5.
3, a kind of medicine for the treatment of neurasthenia according to claim 1 is characterized in that the A group is: Radix Panacis Quinquefolii: 4.9～9.1, Radix Polygalae: 2.9～8.1, the Radix Aucklandiae: 2.9～8.1, Cornu Cervi Pantotrichum: 2.9～8.1, Concha Margaritifera: 4.9～9.1, Dens Draconis: 4.9～9.1, Concha Ostreae: 3.9～9.1, Semen Ziziphi Spinosae (parched): 4.9～9.1, succinum: 3.9～8.1, Magnetitum: 3.9～8.1, Massa Medicata Fermentata: 2.9～7.1, Fructus Citri Sarcodactylis: 2.9～7.1, Poria cum Radix Pini: 3.9～9.1, Ganoderma: 4.9～9.1, Radix Curcumae: 3.9～9.1, Moschus: 1.9～7.1; The B group is: Radix Bupleuri: 3.9～9.1, the Radix Paeoniae Alba: 3.9～9.1, Rhizoma Pinelliae Preparatum: 3.9～9.1, Semen Coicis: 3.9～9.1, Fructus Schisandrae Chinensis: 3.9～9.1, Caulis Polygoni Multiflori: 3.9～9.1, Bulbus Lilii: 3.9～9.1, the Radix Rehmanniae: 3.9～9.1, Rhizoma Gastrodiae: 3.9～9.1, Ramulus Uncariae Cum Uncis: 3.9～9.1, Medulla Junci: 2.9～8.1, Caulis Bambusae In Taenia: 2.9～8.1, Spica Prunellae: 2.9～8.1, Flos Chrysanthemi: 2.9～8.1, Fructus Tritici Levis: 3.9～9.1, Fructus Jujubae: 2.9～8.1, Radix Glycyrrhizae: 2.9～8.1, Folium Pini: 2.9～8.1, Rhizoma Acori Graminei: 3.9～9.1, Folium Kaki: 2.9～8.1, Rhizoma et radix valerianae: 3.9～9.1, Flos Albiziae: 2.9～8.1, Fructus Gardeniae: 2.9～8.1, Radix Angelicae Sinensis: 2.9～8.1, the Radix Astragali: 3.9～9.1, Carapax et Plastrum Testudinis: 2.9～8.1, Rhizoma Dioscoreae: 2.9～8.1, Radix Ophiopogonis: 3.9～9.1.
4, a kind of medicine for the treatment of neurasthenia according to claim 1 is characterized in that the A group is: Radix Panacis Quinquefolii: 5, Radix Polygalae: 4, the Radix Aucklandiae: 4, Cornu Cervi Pantotrichum: 4, Concha Margaritifera: 5, Dens Draconis: 5, Concha Ostreae: 5, Semen Ziziphi Spinosae (parched): 5, succinum: 5, Magnetitum: 5, Massa Medicata Fermentata: 4, Fructus Citri Sarcodactylis: 4, Poria cum Radix Pini: 5, Ganoderma: 5, Radix Curcumae: 5, Moschus: 3; The B group is: Radix Bupleuri: 5, the Radix Paeoniae Alba: 5, Rhizoma Pinelliae Preparatum: 5, Semen Coicis: 5, Fructus Schisandrae Chinensis: 5, Caulis Polygoni Multiflori: 5, Bulbus Lilii: 5, the Radix Rehmanniae: 5, Rhizoma Gastrodiae: 5, Ramulus Uncariae Cum Uncis: 5, Medulla Junci: 4, Caulis Bambusae In Taenia: 4, Spica Prunellae: 4, Flos Chrysanthemi: 4, Fructus Tritici Levis: 5, Fructus Jujubae: 4, Radix Glycyrrhizae: 4, Folium Pini: 4, Rhizoma Acori Graminei: 5, Folium Kaki: 4, Rhizoma et radix valerianae: 5, Flos Albiziae: 4, Fructus Gardeniae: 4, Radix Angelicae Sinensis: 4, the Radix Astragali: 5, Carapax et Plastrum Testudinis: 4, Rhizoma Dioscoreae: 4, Radix Ophiopogonis: 5.
5, a kind of manufacture method of medicine of treatment neurasthenia as claimed in claim 1, it is standby to it is characterized in that the raw material powder that described A organizes is broken into 100～150 purpose fine powders, the raw material water of B group is decocted twice, merge decoction liquor twice, relative density is 1.2～1.3 clear paste when being concentrated into 60～65 ℃, the clear paste mixing and stirring of material powder that A is organized and B group raw material is made the watered pill and is got final product then.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100098886A CN1298383C (en) | 2005-04-13 | 2005-04-13 | Medicine for treating neurasthenia and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100098886A CN1298383C (en) | 2005-04-13 | 2005-04-13 | Medicine for treating neurasthenia and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1686496A CN1686496A (en) | 2005-10-26 |
| CN1298383C true CN1298383C (en) | 2007-02-07 |
Family
ID=35304538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100098886A Expired - Fee Related CN1298383C (en) | 2005-04-13 | 2005-04-13 | Medicine for treating neurasthenia and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1298383C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103142910A (en) * | 2013-03-08 | 2013-06-12 | 张风华 | Spirit-quieting navel paste |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100394951C (en) * | 2006-01-26 | 2008-06-18 | 王信锁 | Medicine for treating insomnia and preparation method thereof |
| CN101062330B (en) * | 2006-04-26 | 2011-01-19 | 成都地奥九泓制药厂 | Chinese medicine composition for improving sleeping and preparing method thereof |
| CN1994451B (en) * | 2006-12-27 | 2010-06-02 | 河南太龙药业股份有限公司 | Chinese medicinal composition for treating depression, its preparation method and application |
| CN101229247B (en) * | 2007-12-28 | 2011-06-01 | 重庆理工大学 | Medicine preparation for treating insomnia and preparing method thereof |
| CN101703622B (en) * | 2009-09-17 | 2013-04-17 | 杭州六易科技有限公司 | Preparation method of buccal tablet for improving sleeping |
| CN102258742B (en) * | 2010-05-27 | 2014-04-23 | 倪健 | Chinese medicinal medicine composition for treating depression and preparation method thereof |
| CN101912434B (en) * | 2010-07-30 | 2012-01-25 | 郑家桂 | Medicament for treating hypertension and insomnia and preparation method thereof |
| CN101947263B (en) * | 2010-09-01 | 2011-09-07 | 刘思波 | Medicament for treating neurasthenia and insomnia |
| CN102178777B (en) * | 2011-04-15 | 2012-07-04 | 刘晓艳 | Chinese patent drug for treating nervous breakdown |
| CN102225164B (en) * | 2011-05-20 | 2012-11-14 | 滕淑玲 | Bag for treating amnesia and calming nerves and preparation method thereof |
| CN102512633B (en) * | 2011-12-23 | 2014-03-12 | 赵丽华 | Traditional Chinese medicinal composition for treating insomnia |
| CN102552671B (en) * | 2012-01-12 | 2013-08-28 | 李玉梅 | Medicament for curing neurasthenia |
| CN102698094B (en) * | 2012-06-18 | 2013-07-10 | 田冬梅 | Medicament for treating female depression |
| CN102784308A (en) * | 2012-07-24 | 2012-11-21 | 马千里 | Chinese medicine composition for treating neurasthenia |
| CN102861295B (en) * | 2012-09-17 | 2014-10-22 | 袁兵 | Traditional Chinese medicine preparation for treating neurasthenia |
| CN103656519A (en) * | 2013-12-16 | 2014-03-26 | 青岛百瑞吉生物工程有限公司 | Traditional Chinese medicine preparation for curing neurasthenia as well as preparation method and application thereof |
| CN103961578A (en) * | 2014-05-15 | 2014-08-06 | 吴春来 | Traditional Chinese medicine medicinal liquor for treating neurasthenia |
| CN104306525A (en) * | 2014-10-23 | 2015-01-28 | 张益玲 | Traditional Chinese medicine preparation for treating neurasthenia |
| CN105267729A (en) * | 2015-02-12 | 2016-01-27 | 济南舜景医药科技有限公司 | Traditional Chinese medicine for treating insomnia |
| CN105148189A (en) * | 2015-09-09 | 2015-12-16 | 孔令刚 | Traditional Chinese medicine preparation for curing insomnia |
| CN105031481A (en) * | 2015-09-18 | 2015-11-11 | 全椒先奇医药科技有限公司 | Pharmaceutic preparation for treating neurasthenia |
| CN105747721A (en) * | 2016-02-28 | 2016-07-13 | 宁波高新区苗姑养生科技有限公司 | Health care pillow for preventing and treating childhood phobia |
| CN105902569B (en) * | 2016-05-26 | 2019-07-09 | 吉林省中韩动物科学研究院 | Improve the composition and its preparation method and application of sleep disturbance |
| CN106930101B (en) * | 2017-02-26 | 2019-07-30 | 浙江峰赫纺织有限公司 | A kind of pillow-cover towel fabric of relieving mental strain and helping sleep |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1085788A (en) * | 1993-06-26 | 1994-04-27 | 长春市白山药物开发研究所 | Oral liquid |
-
2005
- 2005-04-13 CN CNB2005100098886A patent/CN1298383C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1085788A (en) * | 1993-06-26 | 1994-04-27 | 长春市白山药物开发研究所 | Oral liquid |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103142910A (en) * | 2013-03-08 | 2013-06-12 | 张风华 | Spirit-quieting navel paste |
| CN103142910B (en) * | 2013-03-08 | 2014-07-09 | 张风华 | Spirit-quieting navel paste |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1686496A (en) | 2005-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1298383C (en) | Medicine for treating neurasthenia and its preparation method | |
| CN101711850B (en) | Traditional Chinese medicine composition for treating symptoms of myocardial ischemia, palpitation and severe palpitation and preparation method | |
| CN102233112B (en) | Pharmaceutical composition for treatment of lumbar disc herniation and preparation method thereof | |
| CN101485830A (en) | Pure Chinese medicine anti-aging health-care capsule | |
| CN107715067B (en) | Pharmaceutical composition for conditioning blood stasis constitution and preparation method and application thereof | |
| CN104922543A (en) | Medicine composite for treating amenorrhea and preparation method thereof | |
| CN101797352A (en) | Chinese medicinal composition for treating lassitude hypodynamia and preparation method thereof | |
| CN103127472B (en) | Traditional Chinese medicine compound for refractory insomnia | |
| CN101700336B (en) | Chinese herba preparation for curing craniocerebra trauma residual headache and preparation method | |
| CN103479754B (en) | Hypotensive drug and preparation method thereof | |
| CN1352983A (en) | Chinese medicine for treating hypertension | |
| CN105796845A (en) | Application of medicine composition in preparing medicine for treating female climacteric syndromes | |
| CN101549078A (en) | Pharmaceutical composition for treating intractable insomnia and preparation method thereof | |
| CN115779064A (en) | Astragalus root strengthening body resistance and preparation and application thereof | |
| CN105535127A (en) | Foot bath powder containing folium artemisiae argyi dregs and achieving sleep improvement function and preparation method thereof | |
| CN104938727A (en) | Preparation method of insomnia resistance substitutional tea | |
| CN104815232A (en) | Traditional Chinese medicine preparation for treating primary pulmonary hypertension and preparation method thereof | |
| CN101675983A (en) | Warming and tonifying agent for qi-deficiency syndrome | |
| CN104524479B (en) | A kind of Chinese medicine composition for treating premenstrual syndrome and preparation method thereof | |
| CN104258359A (en) | Traditional Chinese medicine combination for curing pregnancy reaction and preparation method of preparations thereof | |
| CN104042981A (en) | Medicament for treating postnatal constipation and preparation method thereof | |
| CN101391001A (en) | Traditional Chinese medicine composition for preventing altitude stress and preparation method thereof | |
| CN105963505A (en) | Traditional Chinese medicinal foot bath powder capable of treating insomnia | |
| CN105362630A (en) | Climacteric syndrome treatment pharmaceutical composition and preparation method thereof | |
| CN104920742A (en) | Anti-insomnia substitutional tea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070207 |